Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole

W. J M Jansen; H. M. Pinedo; C. M. Kuiper; C. Lincke; U. Bamberger; A. Heckel; E. Boven

Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole

W. J M Jansen, H. M. Pinedo, C. M. Kuiper, C. Lincke, U. Bamberger, A. Heckel, E. Boven

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Modulators of the 'classical' multidrug resistance (mdr) phenotype have low efficacy in patients with solid tumors. We analyzed BIBW22BS, 4-[N-(2-hydroxy-2-met-hyl-propyl)-ethanolamino]-2,7-bis(cis-2,6-dimethyl-morpho-lino)- 6-phenylpteridine, a derivative of dipyridamole, for its higher potential to modulate mdr. Materials and methods: Four human malignant cell lines: BRO, A2780, GLC₄, SW1573, the Pgp-positive sublines: BRO/mdrl.l, 2780^AD and the non-Pgp sublines: GLC₄/ADR, SW1573/2R120 were used in vitro to investigate BIBW22BS as a modulator of the antiproliferative effects of vincristine and doxorabicin and to compare the potency of BIBW22BS with that of dipyridamole, verapamil, bepridil and flunarizine. BRO/mdrl.l s.c. well-established xenografts in nude mice were used to study the modulating properties of BIBW22BS 50 mg/kg i.v. followed after one h by vincristine 1 mg/kg i.p. or doxorubicin 8 mg/kg i.p. weekly × 2. Results: BIBW22BS was 20- to 100-fold more potent than dipyridamole in the reversal of resistance in the Pgp-positive sublines. Reversal of resistance was obtained in a dose-dependent manner and was complete at concentrations of 0.5-2.5 (iM. At non-toxic, equimolar concentrations of 1.0 piM BIBW22BS showed higher modulating potency than the calcium-channel blockers. BIBW22BS did not affect resistance in the non-Pgp sublines. BRO/mdrl.l s.c. xenografts have stable multidrug-resistance characteristics upon serial transplantation. BIBW22BS, vincristine, or doxorubicin as single agents were not effective in vivo, while the addition of BIBW22BS could significantly reduce the tumor growth expressed as the T/C% of vincristine from 109% to 48% and that of doxorabicin from 55% to 32%. However, reversal of vincristine resistance in BRO/mdrl.l xenografts was not complete when compared to the efficacy of vincristine in BRO xenografts. Conclusion: The results encourage the further preclinical development of BIBW22BS as a modulator of 'classical' multidrug resistance in cancer patients.

Original language	English (US)
Pages (from-to)	733-739
Number of pages	7
Journal	Annals of Oncology
Volume	5
Issue number	8
State	Published - Oct 1994
Externally published	Yes

Keywords

BIBW22BS
Dipyridamole
Human tumor xenografts
Multidrug resistance
Verapamil

ASJC Scopus subject areas

Statistics, Probability and Uncertainty
Applied Mathematics
Public Health, Environmental and Occupational Health
Neuropsychology and Physiological Psychology
Hematology
Oncology
Cancer Research

Cite this

@article{7069e2c1565a4e38902dc7ee6cb63f58,

title = "Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole",

abstract = "Background: Modulators of the 'classical' multidrug resistance (mdr) phenotype have low efficacy in patients with solid tumors. We analyzed BIBW22BS, 4-[N-(2-hydroxy-2-met-hyl-propyl)-ethanolamino]-2,7-bis(cis-2,6-dimethyl-morpho-lino)- 6-phenylpteridine, a derivative of dipyridamole, for its higher potential to modulate mdr. Materials and methods: Four human malignant cell lines: BRO, A2780, GLC4, SW1573, the Pgp-positive sublines: BRO/mdrl.l, 2780AD and the non-Pgp sublines: GLC4/ADR, SW1573/2R120 were used in vitro to investigate BIBW22BS as a modulator of the antiproliferative effects of vincristine and doxorabicin and to compare the potency of BIBW22BS with that of dipyridamole, verapamil, bepridil and flunarizine. BRO/mdrl.l s.c. well-established xenografts in nude mice were used to study the modulating properties of BIBW22BS 50 mg/kg i.v. followed after one h by vincristine 1 mg/kg i.p. or doxorubicin 8 mg/kg i.p. weekly × 2. Results: BIBW22BS was 20- to 100-fold more potent than dipyridamole in the reversal of resistance in the Pgp-positive sublines. Reversal of resistance was obtained in a dose-dependent manner and was complete at concentrations of 0.5-2.5 (iM. At non-toxic, equimolar concentrations of 1.0 piM BIBW22BS showed higher modulating potency than the calcium-channel blockers. BIBW22BS did not affect resistance in the non-Pgp sublines. BRO/mdrl.l s.c. xenografts have stable multidrug-resistance characteristics upon serial transplantation. BIBW22BS, vincristine, or doxorubicin as single agents were not effective in vivo, while the addition of BIBW22BS could significantly reduce the tumor growth expressed as the T/C% of vincristine from 109% to 48% and that of doxorabicin from 55% to 32%. However, reversal of vincristine resistance in BRO/mdrl.l xenografts was not complete when compared to the efficacy of vincristine in BRO xenografts. Conclusion: The results encourage the further preclinical development of BIBW22BS as a modulator of 'classical' multidrug resistance in cancer patients.",

keywords = "BIBW22BS, Dipyridamole, Human tumor xenografts, Multidrug resistance, Verapamil",

author = "Jansen, {W. J M} and Pinedo, {H. M.} and Kuiper, {C. M.} and C. Lincke and U. Bamberger and A. Heckel and E. Boven",

year = "1994",

month = oct,

language = "English (US)",

volume = "5",

pages = "733--739",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole

AU - Jansen, W. J M

AU - Pinedo, H. M.

AU - Kuiper, C. M.

AU - Lincke, C.

AU - Bamberger, U.

AU - Heckel, A.

AU - Boven, E.

PY - 1994/10

Y1 - 1994/10

N2 - Background: Modulators of the 'classical' multidrug resistance (mdr) phenotype have low efficacy in patients with solid tumors. We analyzed BIBW22BS, 4-[N-(2-hydroxy-2-met-hyl-propyl)-ethanolamino]-2,7-bis(cis-2,6-dimethyl-morpho-lino)- 6-phenylpteridine, a derivative of dipyridamole, for its higher potential to modulate mdr. Materials and methods: Four human malignant cell lines: BRO, A2780, GLC4, SW1573, the Pgp-positive sublines: BRO/mdrl.l, 2780AD and the non-Pgp sublines: GLC4/ADR, SW1573/2R120 were used in vitro to investigate BIBW22BS as a modulator of the antiproliferative effects of vincristine and doxorabicin and to compare the potency of BIBW22BS with that of dipyridamole, verapamil, bepridil and flunarizine. BRO/mdrl.l s.c. well-established xenografts in nude mice were used to study the modulating properties of BIBW22BS 50 mg/kg i.v. followed after one h by vincristine 1 mg/kg i.p. or doxorubicin 8 mg/kg i.p. weekly × 2. Results: BIBW22BS was 20- to 100-fold more potent than dipyridamole in the reversal of resistance in the Pgp-positive sublines. Reversal of resistance was obtained in a dose-dependent manner and was complete at concentrations of 0.5-2.5 (iM. At non-toxic, equimolar concentrations of 1.0 piM BIBW22BS showed higher modulating potency than the calcium-channel blockers. BIBW22BS did not affect resistance in the non-Pgp sublines. BRO/mdrl.l s.c. xenografts have stable multidrug-resistance characteristics upon serial transplantation. BIBW22BS, vincristine, or doxorubicin as single agents were not effective in vivo, while the addition of BIBW22BS could significantly reduce the tumor growth expressed as the T/C% of vincristine from 109% to 48% and that of doxorabicin from 55% to 32%. However, reversal of vincristine resistance in BRO/mdrl.l xenografts was not complete when compared to the efficacy of vincristine in BRO xenografts. Conclusion: The results encourage the further preclinical development of BIBW22BS as a modulator of 'classical' multidrug resistance in cancer patients.

AB - Background: Modulators of the 'classical' multidrug resistance (mdr) phenotype have low efficacy in patients with solid tumors. We analyzed BIBW22BS, 4-[N-(2-hydroxy-2-met-hyl-propyl)-ethanolamino]-2,7-bis(cis-2,6-dimethyl-morpho-lino)- 6-phenylpteridine, a derivative of dipyridamole, for its higher potential to modulate mdr. Materials and methods: Four human malignant cell lines: BRO, A2780, GLC4, SW1573, the Pgp-positive sublines: BRO/mdrl.l, 2780AD and the non-Pgp sublines: GLC4/ADR, SW1573/2R120 were used in vitro to investigate BIBW22BS as a modulator of the antiproliferative effects of vincristine and doxorabicin and to compare the potency of BIBW22BS with that of dipyridamole, verapamil, bepridil and flunarizine. BRO/mdrl.l s.c. well-established xenografts in nude mice were used to study the modulating properties of BIBW22BS 50 mg/kg i.v. followed after one h by vincristine 1 mg/kg i.p. or doxorubicin 8 mg/kg i.p. weekly × 2. Results: BIBW22BS was 20- to 100-fold more potent than dipyridamole in the reversal of resistance in the Pgp-positive sublines. Reversal of resistance was obtained in a dose-dependent manner and was complete at concentrations of 0.5-2.5 (iM. At non-toxic, equimolar concentrations of 1.0 piM BIBW22BS showed higher modulating potency than the calcium-channel blockers. BIBW22BS did not affect resistance in the non-Pgp sublines. BRO/mdrl.l s.c. xenografts have stable multidrug-resistance characteristics upon serial transplantation. BIBW22BS, vincristine, or doxorubicin as single agents were not effective in vivo, while the addition of BIBW22BS could significantly reduce the tumor growth expressed as the T/C% of vincristine from 109% to 48% and that of doxorabicin from 55% to 32%. However, reversal of vincristine resistance in BRO/mdrl.l xenografts was not complete when compared to the efficacy of vincristine in BRO xenografts. Conclusion: The results encourage the further preclinical development of BIBW22BS as a modulator of 'classical' multidrug resistance in cancer patients.

KW - BIBW22BS

KW - Dipyridamole

KW - Human tumor xenografts

KW - Multidrug resistance

KW - Verapamil

UR - http://www.scopus.com/inward/record.url?scp=0028093036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028093036&partnerID=8YFLogxK

M3 - Article

C2 - 7826906

AN - SCOPUS:0028093036

SN - 0923-7534

VL - 5

SP - 733

EP - 739

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -

Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this